Report Overview

The EU Inflammatory Bowel Disease market size stood at round USD $0.1 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 5.1% during the forecast period

Inflammatory bowel disease (IBD) describes a group of disorders which are caused due to the inflammation of the intestine. Various symptoms of IBD are diarrhea, blood or mucus in stool, fever, abdominal pain, and others. In order to diagnose IBD, various tests such as C - reactive protein (CPR), Complete Blood Count (CBC), and calprotectin test are performed



Market Drivers

The factors driving the IBD(Inflammatory Bowel Disease) in Europe consists of numerous key economies including the UK, Germany, France, Spain, Italy, and Norway which register a significant share in the market. The changing lifestyle and significant share of the population which engages in smoking is also one of the key reasons which are expected to increase the prevalence of IBD in the region. The European Federation of Crohn's & Ulcerative Colitis Associations is one such organization in the region which engages in the monitoring of IBD in the region and conducting clinical studies so as to develop efficient treatment alternative for IBD. Furthermore, the prevalence of IBD increases with a change in eating patterns and unhealthy eating and smoking practices. It is observed that smoking is one of the key reasons which promotes the prevalence of IBD in the working age population. The percentage of population smoking in the UK is majorly between the age group of 25-34. Owing to this, the prevalence of IBD is expected to increase, thereby creating opportunities for the growth of the market in the near future